Generic Name and Formulations:
Ioxilan 300mgI/mL, 350mgI/mL; soln for IV inj; preservative-free.
Indications for OXILAN:
Intraarterial: For cerebral arteriography (300mgI/mL). For coronary arteriography and left ventriculography, visceral angiography, aortography, and peripheral arteriography (350mgI/mL). IV: For excretory urography and contrast enhanced computed tomographic (CECT) imaging of the head and body (300mgI/mL and 350mgI/mL).
Individualize. Intraarterial procedures: Left and right coronary: 2–10mL. Left ventricle: 25–50mL. Aortography and selective visceral: see literature. Aortic bifurcation for distal runoff: 45–100mL. Subclavian or femoral artery: 10–40mL. Total dose for procedure should not exceed 250mL. Cerebral arteriography: 8–12mL; total dose for procedure should not exceed 150mL. IV procedures: Excretory urography: 250–390mgI/kg; total dose for procedure should not exceed 100mL. CECT of the head: 100–200mL (300mgI/mL) or 86–172mL (350mgI/mL); total dose for procedure should not exceed 200mL. CECT of body: 50–200mL (300mgI/mL) or 43–172mL (350mgI/mL); total dose for procedure should not exceed 200mL.
Should be administered by professional trained in use of radiopaque agents in appropriate facilities with emergency treatment readily available. Homocystinuria: avoid. Severe renal impairment. Combined renal and hepatic disease. Combined renal and cardiac disease. CHF. Diabetes. Severe thyrotoxicosis. Myelomatosis. Anuria. Pheochromocytoma. Homozygous sickle cell disease. Immune disorders. Maintain adequate hydration. History of sever cutaneous hypersensitivity reaction; avoid. Avoid extravasation. Elderly. Pregnancy (Cat.B). Nursing mothers: not recommended.
Nonionic contrast agent.
Recently received cholecystographic agents in patients with hepatic or biliary disorder; increased risk of renal toxicity. Do not mix with other drugs. Radioactive iodine uptake studies may not accurately reflect thyroid function for up to 16 days.
Headache, fever, hematoma at inj site, chills, angina, hypertension, bradycardia, hypotension, GI upset, dizziness, urticaria, rash; thromboembolic events, hypersensitivity reactions, severe cutaneous reactions (eg, SJS/TEN, AGEP, DRESS).
Single-dose bottles (50mL, 100mL, 150mL, 200mL)—10
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- Feasibility of Clinical Production of Autologous NKG2D CAR-T
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline